FDA joins Tox21 collaboration

The FDA has signed on with the Tox21 collaboration. The regulator joins the EPA, the National Institute of Environmental Health Sciences National Toxicology Program, and the National Institute of Health Chemical Genomics Center in developing models to predict how chemicals will affect human health and the environment. Release


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.